Treace Medical Concepts (Treace Medical Concepts) ROCE % : -34.50% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Treace Medical Concepts's annualized ROCE % for the quarter that ended in Mar. 2024 was -34.50%.

Treace Medical Concepts ROCE % Historical Data

The historical data trend for Treace Medical Concepts's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts ROCE % Chart

Treace Medical Concepts Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-15.30

3.25

-21.58

-30.56

-26.43

Treace Medical Concepts Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial													-27.45	-19.73	-30.41	-9.62	-34.50

Treace Medical Concepts ROCE % Calculation

Treace Medical Concepts's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-44.36	/	( ( (159.024 - 30.245)	+	(251.907 - 45.033) )	/ 2 )
	=	-44.36	/	( (128.779	+	206.874)	/ 2 )
	=	-44.36	/	167.8265
	=	-26.43 %

Treace Medical Concepts's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-69.436	/	( ( (251.907 - 45.033)	+	(242.726 - 47.049) )	/ 2 )
	=	-69.436	/	( ( 206.874	+	195.677 )	/ 2 )
	=	-69.436	/	201.2755
	=	-34.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Treace Medical Concepts (NAS:TMCI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Treace Medical Concepts ROCE % Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Treace Medical Concepts (Treace Medical Concepts) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081

Website

https://www.treace.com

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.

Executives

F Barry Bays	director
Betsy Hanna	director	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain	director	3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan	officer: See Remarks	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace	director	117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott	director	1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie	director
Daniel E. Owens	officer: Chief HR Officer	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder	officer: *See "Remarks"	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair	officer: Chief Financial Officer	C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti	officer: Sr. VP, Sales	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace	director, 10 percent owner, officer: Chief Executive Officer	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
John R Treace	director	5677 AIRLINE RD, ARLINGTON VA 38002